Logo image of ZK

ZEEKR INTELLIGENT TECHNO-ADR (ZK) Stock Fundamental Analysis

NYSE:ZK - New York Stock Exchange, Inc. - US98923K1034 - ADR - Currency: USD

24.47  -0.03 (-0.12%)

After market: 24.55 +0.08 (+0.33%)

Fundamental Rating

2

ZK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 40 industry peers in the Automobiles industry. ZK may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ZK is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ZK has reported negative net income.
ZK Yearly Net Income VS EBIT VS OCF VS FCFZK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 2B -2B -4B -6B -8B

1.2 Ratios

ZK has a Return On Assets of -25.74%. This is in the lower half of the industry: ZK underperforms 63.16% of its industry peers.
Industry RankSector Rank
ROA -25.74%
ROE N/A
ROIC N/A
ROA(3y)-36.02%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZK Yearly ROA, ROE, ROICZK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -500 -1K -1.5K -2K

1.3 Margins

The Gross Margin of ZK (15.05%) is better than 63.16% of its industry peers.
The Profit Margin and Operating Margin are not available for ZK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 15.05%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZK Yearly Profit, Operating, Gross MarginsZK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 0 -20 -40 -60

More info and screens

1

2. Health

2.1 Basic Checks

ZK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The debt/assets ratio for ZK has been reduced compared to a year ago.
ZK Yearly Total Debt VS Total AssetsZK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 5B 10B 15B 20B 25B

2.2 Solvency

Based on the Altman-Z score of 0.29, we must say that ZK is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ZK (0.29) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.29
ROIC/WACCN/A
WACC12.82%
ZK Yearly LT Debt VS Equity VS FCFZK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 5B -5B

2.3 Liquidity

ZK has a Current Ratio of 0.64. This is a bad value and indicates that ZK is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.64, ZK is not doing good in the industry: 76.32% of the companies in the same industry are doing better.
ZK has a Quick Ratio of 0.64. This is a bad value and indicates that ZK is not financially healthy enough and could expect problems in meeting its short term obligations.
ZK's Quick ratio of 0.52 is on the low side compared to the rest of the industry. ZK is outperformed by 73.68% of its industry peers.
Industry RankSector Rank
Current Ratio 0.64
Quick Ratio 0.52
ZK Yearly Current Assets VS Current LiabilitesZK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 10B 20B 30B

More info and screens

4

3. Growth

3.1 Past

ZK shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.21%.
The Revenue has grown by 61.99% in the past year. This is a very strong growth!
EPS 1Y (TTM)-5.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.43%
Revenue 1Y (TTM)61.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-81.37%

3.2 Future

ZK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.17% yearly.
ZK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.90% yearly.
EPS Next Y55.51%
EPS Next 2Y34.95%
EPS Next 3Y29.17%
EPS Next 5YN/A
Revenue Next Year58.23%
Revenue Next 2Y47.51%
Revenue Next 3Y40.9%
Revenue Next 5YN/A

3.3 Evolution

ZK Yearly Revenue VS EstimatesZK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 10B 20B 30B 40B 50B
ZK Yearly EPS VS EstimatesZK Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 0.5 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZK. In the last year negative earnings were reported.
Also next year ZK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZK Price Earnings VS Forward Price EarningsZK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 -200 400

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZK Per share dataZK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

A more expensive valuation may be justified as ZK's earnings are expected to grow with 29.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.95%
EPS Next 3Y29.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZEEKR INTELLIGENT TECHNO-ADR

NYSE:ZK (2/21/2025, 8:04:00 PM)

After market: 24.55 +0.08 (+0.33%)

24.47

-0.03 (-0.12%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupAutomobiles & Components
GICS IndustryAutomobiles
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners2.46%
Inst Owner Change77.77%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap6.06B
Analysts85.33
Price Target36.76 (50.22%)
Short Float %0.76%
Short Ratio2.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48.18%
Min EPS beat(2)47.55%
Max EPS beat(2)48.81%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.31%
Min Revenue beat(2)-9.48%
Max Revenue beat(2)8.87%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.49%
PT rev (3m)12.48%
EPS NQ rev (1m)-18.04%
EPS NQ rev (3m)92.27%
EPS NY rev (1m)0.48%
EPS NY rev (3m)37.78%
Revenue NQ rev (1m)-10.68%
Revenue NQ rev (3m)-1%
Revenue NY rev (1m)-0.21%
Revenue NY rev (3m)-3.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.63
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.81
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS38.67
BVpS-5.92
TBVpS-6.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.74%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 15.05%
FCFM N/A
ROA(3y)-36.02%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover2.12
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.64
Quick Ratio 0.52
Altman-Z 0.29
F-ScoreN/A
WACC12.82%
ROIC/WACCN/A
Cap/Depr(3y)511.43%
Cap/Depr(5y)N/A
Cap/Sales(3y)6.05%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.43%
EPS Next Y55.51%
EPS Next 2Y34.95%
EPS Next 3Y29.17%
EPS Next 5YN/A
Revenue 1Y (TTM)61.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-81.37%
Revenue Next Year58.23%
Revenue Next 2Y47.51%
Revenue Next 3Y40.9%
Revenue Next 5YN/A
EBIT growth 1Y-14.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.45%
EBIT Next 3Y38.2%
EBIT Next 5YN/A
FCF growth 1Y108.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y164.57%
OCF growth 3YN/A
OCF growth 5YN/A